• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.

  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

Angiogenesis

Membrane-free microvascular formation and growth
through an extracellular matrix (ECM).

Why Angiogenesis?

The loss of vascular integrity plays a rate-limiting role in the onset and progression of diseases, such as atherosclerosis and cancer, and conditions such as chronic inflammation and ischemia. Therefore, detailed knowledge of the mechanisms of microvascular loss or the formation of novel vascular structures such as those generated by angiogenesis is of major importance.

Angiogenic sprouting is the growth of new blood vessels from pre-existing vessels, which is orchestrated by cues from within the cellular microenvironment, such as biochemical gradients and perfusion. Many of these cues are missing in current in vitro models of angiogenic sprouting. We have optimized the OrganoPlate® platform for growing perfusable 3D angiogenic sprouts, including tip-stalk cell hierarchy and anastomosis. The platform integrates both perfusion and the generation of stable biomolecular gradients and demonstrates its potential to study more physiologically relevant angiogenic sprouting and microvascular stabilization.

Speak With an Expert

Features

  • Perfused 3D microvasculature
  • Stable capillary structure for 4+ days
  • Tip-stalk cell hierarchy & anastomosis
  • Investigate microvascular damage, tumor angiogenesis, fibrosis

 

Assays

  • Sprout visualization through calcein-AM labeling
  • Sprout quantification (based on fluorescent images)
  • Perfusion assay, using fluorescent dyes
  • Expression of adherens and tight junction markers (immunostaining)
  • Expression of transporters (RNA isolation and PCR, or immunostaining)

How to grow 3D angiogenesis models?


OrganoPlate allows you to study angiogenesis in 3D. In this video, we explain to you in a few steps how we develop 3D angiogenesis models at MIMETAS. Watch it now and learn how we can support your research.

Our Technology

Related

Publications

More Publications

Our Offerings

  • Partnerships
    We offer tailored partnerships to support and transform drug discovery.
  • Services
    MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.
  • OrganoReady®
    Ready-to-use 3D tissue models for drug exposure, transport, and permeability studies.



Product Overview

Get Inspired

Case Study
Robust angiogenesis inhibition assay in collaboration with Leiden University Medical Center (LUMC)


Webinar
Enhancing 3D Disease Models: Automated, High-throughput Phenotypic Screening with Organ-on-a-Chip

Whitepaper
High-throughput phenotypic screening with Organ-on-a-chip: a perfused 3D microfluidic angiogenesis assay

Explore Our Webinars

Want to know more?


Get up to speed with 3D tissue culture and learn how OrganoPlate® supports your research needs.

Knowledge Center Contact us

What customers say
'
Our exciting collaboration enables our research and early development group to apply state-of-the-art organ-on-a-chip technology in the modeling of IBD and HBV. These models have the potential to improve our understanding of disease biology and transform

James Sabry, Global Head
Roche Pharma Partnering

The 'I' in MIMETAS
'
Tackling challenges together.

Linda Gijzen
Scientific Project Lead

What customers say
'
"The OrganoReady Colon Caco-2, combined with the OrganoTEER, have become our gold standard in vitro model for the screening of intestinal barrier disruptors at SIAF. "

Cezmi Akdis
Director SIAF
University Zurich

What customers say
'
The OrganoPlate Caco-2 model is for us, at Merck, the most suitable platform offering at the same time scalability, speed, robustness, ease of handling, with low compound needs.

Philip Hewitt
Head of Early Investigative Toxicology
Merck KGaA

The 'I' in MIMETAS
Chiwan Chiang
Marketing Specialist
'
A day without
laughter is a day wasted.
Read more
What customers say
'
Mimetas' tumor infiltration platform demonstrated a therapeutic effect of our compound on immune cell recruitment: we’re very excited by these proof of concept data

Scientist
From a top pharma

The 'I' in MIMETAS
Jos Joore
CEO
'
We want to
empower research on complex tissue biology.
Read more
What customers say
'
Often you have to compromise it’s either the throughput or it’s the complexity of the model. Getting both in the same platform… no other platform can do that!

Scientist
From a top pharma

The 'I' in MIMETAS
Nienke Wevers
Senior Scientist
'
Nothing ventured, nothing gained.
Read more
What customers say
'
We were able to measure cell barrier permeabilities in a lung-on-a-chip model demonstrating superior sensitivity and translatability than any other lung cell model we tried before. It was also very easy to scale up our data generation workflow.

Scientist
From a top commercial organization

The 'I' in MIMETAS
Henriëtte Lanz
Director of Model Development
'
It should be
mandatory to
socialize with colleagues.
Read more
What customers say
'
Organoplates opened avenues that were before considered unreachable

Laura Perin, PhD
Children’s Hospital Los Angeles

The 'I' in MIMETAS
Bas Trietsch
Chief Technology Officer
'
We try to help
each other
as a team.
Read more
The 'I' in MIMETAS
Jacquelien Ten Dam
Chief Financial Officer
'
It always seems impossible until it’s done.
Read more
The 'I' in MIMETAS
Paul Vulto
CEO
'
Leveraging who you are, is the key to making a difference!
Read more
The 'I' in MIMETAS
Linda Gijzen
Scientific Project Lead
'
Tackling challenges together.
Read more
The 'I' in MIMETAS
Tina Thakkar
Associate Director of Sales
'
It is not really
work if you are
having fun.
Read more
The 'I' in MIMETAS
Liis Rannamäe
Laboratory Technician
'
Can be summarized in three words - engaging, playful, and innovative.
Read more
The 'I' in MIMETAS
Mieke Doornbos
Vice President Sales & Marketing
'
Celebrate
good times.
Read more
The 'I' in MIMETAS
Frederik Schavemaker
Product Design Engineer
'
Pioneering, bringing the best solutions
for scientific
discovery.
Read more
The 'I' in Mimetas
Remko van Vught
Vice President Business Development
'
Making
a difference
together.
Read more
The 'I' in MIMETAS
Lenie van den Broek
Director Biology Discovery
'
Dynamic and innovative - each day holds a surprise.
Read more
The 'I' in Mimetas
Arnaud Nicolas
Associate Director TechCore
'
Own your flaws.
Read more
Latest Whitepaper
'
Closing the Translational Gap in Cancer Drug Discovery with Comprehensive Tumor Models

Discover insights from six oncology applications of MIMETAS’ 3D tumor models.


Download the whitepaper

New Webinar
'
Phenotypic Disease Modeling for Immuno-Oncology: Putting Targets into Patient Context


Now available on demand.

Watch it here

Press Release
'
MIMETAS and Astellas Enter into Strategic Partnership on Immuno-oncology

The partnership comprises utilizing MIMETAS’ comprehensive tumor models to support the next generation of immuno-oncological therapies.

Read the full article here

News Article
'
First Large-scale Phenotypic Screen Using Organ-on-a-Chip

Leveraging a 3D angiogenesis assay, MIMETAS executed a 1537 kinase inhibitor library screen.


Read the article

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all